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Introduction
europsychological assessment is the normatively
informed application of performance-based assessments
of various cognitive skills. Typically, neuropsychological
assessment is performed with a battery approach, which
involves tests of a variety of cognitive ability areas, with
more than one test per ability area. These ability areas
include skills such as memory, attention, processing speed,
reasoning, judgment, and problem-solving, spatial, and
language functions. These assessments are commonly per-
formed in conjunction with assessments designed to
examine lifelong academic and cognitive achievement and
potential,
1 for a variety of reasons described below. The
assessment battery can be standardized or targeted to the
individual participant in the assessment. Assessment data
may be collected either directly by a psychologist or by
a trained examiner, who performs and scores assessments
and delivers them to the neuropsychologist. While neu-
ropsychological assessments were originally targeted at
individuals who had experienced brain injuries in
wartime,
2 the populations for whom neuropsychological
assessments are useful spans the whole range of neu-
ropsychiatric conditions.
3
Neuropsychological tests are intrinsically performance-
based. They are structured to require individuals to exer-
cise their skills in the presence of an examiner/observer.
Self-reports of functioning, as well as observations of
behavior while performing testing, are critically impor-
tant pieces of information, as described below. Self-
reports of functioning are often affected by the presence
of neuropsychiatric conditions,
4 and do not have the
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Neuropsychological assessment is a performance-based
method to assess cognitive functioning. This method is
used to examine the cognitive consequences of brain dam-
age, brain disease, and severe mental illness. There are sev-
eral specific uses of neuropsychological assessment, includ-
ing collection of diagnostic information, differential
diagnostic information, assessment of treatment response,
and prediction of functional potential and functional
recovery. We anticipate that clinical neuropsychological
assessment will continue to be used, even in the face of
advances in imaging technology, because it is already well
known that the presence of significant brain changes can
be associated with nearly normal cognitive functioning,
while individuals with no lesions detectable on imaging
can have substantial cognitive and functional limitations.     
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same value as performance under standard conditions,
which is compared with normative standards. A critical
concept in neuropsychological assessment is normative
comparison.
5This involves taking the performance of an
individual at the time they are tested and comparing that
performance to reference groups of the same age, sex,
race, and educational attainment. All of these demo-
graphic factors impact performance on the tests in a neu-
ropsychological assessment battery, and interpreting the
test performance of people, regardless of the illness or
injury that they have experienced, is based on compar-
isons with individuals who are similar to them. These
normative comparisons allow for determination whether
an individual is performing as would be expected, given
their lifetime levels of achievements and their educa-
tional attainment, or if their performance is poorer than
expected. Performance that is poorer than expectations
can be quantified and interpreted accordingly.
Definition of a meaningful cognitive deficit
Neuropsychological assessment provides both general
and specific information about current levels of cogni-
tive performance. An average or composite score across
multiple ability areas provides an overall index of how
well a person functions cognitively at the current time.
As noted below, these global scores are the most reliable
results of a neuropsychological assessment. These global
scores are the indices most commonly used to predict
real-world functional milestones and to make judgments
about functioning in conditions where multiple ability
domains are affected (eg, serious mental illness or trau-
matic brain injury).
6
However, it is also important to be able to make judg-
ments about specific differential deficits across ability
areas. For instance, an individual who experiences a focal
stroke or brain injury may have limited cognitive deficits,
with most abilities unchanged. Thus, when making a
judgment about the presence of a single cognitive deficit
such as amnesia or a broader condition such as demen-
tia it is critical to be able to identify exactly what a “dif-
ferential deficit” would be. This judgment process is
complicated by the fact that healthy individuals with no
evidence of, or risk factors for, neuropsychiatric condi-
tions show some variability across their abilities.
7 As a
result, it is important to consider several different fac-
tors when identifying normal variation between ability
areas from neuropsychological deficits.
There are several factors that impact on within-individ-
ual variation across cognitive ability areas. These include
the reliability of the measures, the normative standards
for the measures, and the level of performance of the
individual. Tests with less reliability produce more vari-
able scores at both single assessment and retest. The dis-
crepancies between ability areas that can be interpreted
as truly different from each other also depend on
whether the normative standards for the tests were
developed in a single sample (ie, co-normed) or sepa-
rately.
8 For example, meaningful differences between
individual subtests on intelligence tests such as the
Wechsler Adult intelligence scales
9 are smaller than dif-
ferences between tests that were developed completely
separately from each other, because of their co-norming
on a single sample. Likewise, normative comprehensive
standards for extended neuropsychological assessment
batteries have also been developed with the same pur-
poses in mind.
10 Finally, extremes in performance, both
higher and lower, lead to greater apparent discrepancies
between ability areas. This is because that, at the tails of
the distribution, smaller absolute score differences lead
to larger normative differences.
In terms of interpretation of meaningful differences
between abilities in neuropsychiatric conditions, a widely
accepted rule of for a clinically meaningful difference
between two ability areas is about one-half of a standard
deviation.
11 This translates into about 7 IQ points and
this level of difference has been shown to be detectable
by observers. Specific, multiple studies have suggested
that untrained observers can detect differences in func-
tioning that occur over time that reach this threshold. As
a result, treatment studies for cognitive impairments
would not need to induce treatment effects smaller than
this, because they might not be detectable.
It should be noted that the changes seen in many neu-
ropsychiatric conditions are much more substantial than
this 0.5 SD threshold. As a clear example, data regard-
ing immediate memory changes, particularly rapid for-
getting, at the outset of Alzheimer’s disease (AD) are
considerably more substantial than 0.5 SD. Data exam-
ining differences in performance across ability areas at
the time of diagnosis has suggested memory perfor-
mance about 3.0 SD below that of demographically sim-
ilar healthy controls.
12 Further, differential deficits
between abilities at the time of diagnosis are also sub-
stantial. In that same, very large-scale study, memory
performance was about 2.0 SD below that of confronta-
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13 Although subtle
differences can be detected by observers as described
above, many of the differences between abilities in neu-
ropsychiatric conditions are not subtle.
Conditions where neuropsychological 
assessment provides useful information
Situations where an illness or injury has the potential to
adversely impact on cognitive functioning is one where
neuropsychological assessment is indicated. These situ-
ations include illnesses or injuries that directly impact on
cognition (Degenerative dementias or traumatic brain
injuries) or where the treatment for the illness impacts
on cognitive functioning (chemotherapy for breast can-
cer). Finally, as neuropsychiatric conditions are complex,
many of them have the potential to induce changes in
mood or motivational states that can have secondary
impacts on cognitive functioning. As these secondary
impacts can cause cognitive changes that are as just as
real as those caused by a brain injury, part of a compre-
hensive contemporary neuropsychological assessment
requires an assessment of other factors that may be con-
tributing to impaired cognitive functioning. 
Information obtained from 
neuropsychological assessment
There are several different uses for neuropsychological
assessments. These include assessment for the purpose
of diagnosis, differential diagnosis, prediction of func-
tional potential, measuring treatment response, and clin-
ical correlation with imaging findings. Some of these uses
are related to each other and some are impossible in cer-
tain circumstances, because neuropsychological assess-
ments do not provide information helpful for these tasks.
These uses are presented in Table I.
Diagnosis
Some conditions are defined by the presence of cogni-
tive impairment. A prototypical example is dementia as
defined by the DSM-IV-TR.
14 Dementia requires the
presence of functional deficits and cognitive impair-
ments. These impairments must be in two domains:
memory, and one other cognitive deficit. In contrast to
dementia, amnesia, also defined in DSM-IV-TR, requires
only the presence of memory deficits for its diagnosis.
For these conditions, therefore, neuropsychological
assessment would serve to provide diagnostic informa-
tion, because the presence of specific or multiple cogni-
tive deficits, including memory, would provide informa-
tion for a diagnosis. Similarly there are other conditions,
such as postconcussion syndrome where the presence of
cognitive impairments of various types is required as a
part of the diagnosis. Further, mental retardation
requires the presence of a certain level of current intel-
lectual functioning that can only be obtained psycho-
metrically.
The way the DSM-IV-TR is structured, however, there is
no diagnosis that is confirmed simply as a function of the
data obtained in a neuropsychological assessment. In the
case of dementia, for instance, there are multiple addi-
tional criteria that must be met as well, and many of
these pieces of information are obtained from other
sources. These include history (eg, prior better levels of
functioning), assessment of current adaptive deficits, and
identification of a potential cause of the condition. As
a result, neuropsychological assessments are only part of
the diagnostic process. 
Due to the way the DSM-IV-TR is set up, neuropsycho-
logical assessment does not provide information relevant
to the diagnosis of most conditions where cognitive
impairments are present. For example, many serious
mental illnesses are marked by the presence of substan-
tial cognitive impairments. Schizophrenia,
15 bipolar dis-
order,
16 and major depression
17 have substantial cogni-
tive deficits as a common feature of their presentation,
even in patients with current minimal levels of symp-
toms. Since these impairments are not part of the diag-
nostic criteria, neuropsychological assessment does not
provide diagnostically relevant information. As noted
below, however, there is considerable information that
can be obtained from neuropsychological assessments in
these conditions, particularly in functional and prognos-
tic domains.
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￿ Diagnostic information for detection of dementia or other 
traumatic conditions
￿ Differential diagnosis of dementia vs less complex conditions
￿ Measurement of functional potential
￿ Course of degenerative conditions
￿ Measurement of recovery of functioning 
￿ Measurement of treatment response
Table I. Uses of neuropsychological assessment.
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Differential diagnosis
There are some conditions where neuropsychological
assessment can be important for differential diagnosis.
As noted above, dementia requires memory deficits in
the presence of other cognitive impairments, while
amnesia is diagnosed by the presence of only deficits in
memory. Detection of multiple cognitive impairments
would therefore rule out the presence of amnesia and
argue for a diagnosis of dementia in this case.
Differential diagnosis is much more challenging for most
conditions, however. For example, studies attempting to
differentiate between dementing conditions of different
etiologies, such as vascular dementia as compared with
AD, have found little evidence of differential diagnostic
utility from neuropsychological assessment.
18 In fact, a
fascinating book by Zakzanis et al
19 that broadly
approached this topic has suggested that for many con-
ditions there is very little differential diagnostic infor-
mation contained in a neuropsychological assessment
that even allows for differentiation between healthy pop-
ulations and patients with a variety of neuropsychiatric
conditions. Their meta-analysis includes all of the
research published on neuropsychological test differ-
ences between healthy controls and several neuropsy-
chiatric target populations during the years 1980-1997.
As a result, there is a wealth of detail on how much infor-
mation each of these neuropsychological tests provides
for test-based differential diagnosis of the target popula-
tions compared with healthy comparison subjects.
It is important in this area to consider the differences
between differential diagnosis and statistically signifi-
cant differences in performance across different condi-
tions. An effect size of .6 SD in the difference of two
means, by convention a large effect and easy to detect in
samples as small as 20 individuals per group, is associ-
ated with 62% overlap between the two samples. In
order to be able to tell with 90% certainty that an indi-
vidual’s test score is consistent with a psychiatric or neu-
rological diagnosis and not part of the lower end of the
distribution of healthy, an average difference of about
2.5 SD between populations is required. 
Many statistically significant differences between samples
would fare poorly as candidates for differential diagnosis.
For example, people with schizophrenia routinely have
more significant cognitive deficits than people with bipo-
lar disorder, regardless of the mood state of the bipolar
patients.
20 However, since bipolar patients themselves are
more impaired in their cognitive performance than
healthy people, there is substantial overlap in the distrib-
utions of cognitive performance between people with
schizophrenia and bipolar disorder and minimal differ-
ential diagnostic information available. In contrast to the
differences between people with AD and healthy popu-
lations on delayed recall memory, there is little discrimi-
nation between bipolar and schizophrenia populations.
The distributions of patients with severe mental illness
and healthy people have substantial overlap. As can be
seen in Figure 1, there is considerable overlap in the dis-
tributions of scores on neuropsychological assessments
of people with schizophrenia and healthy people, even
if the means of the distributions are two full standard
deviations apart. The r-BANS
21 is an abbreviated neu-
ropsychological assessment that examines multiple abil-
ity domains in a repeatable format. It is scaled like an
IQ test, with a mean of 100 and standard deviation of 15
in healthy populations. As can be seen in Figure 1,
22 peo-
ple with schizophrenia have a mean level of perfor-
mance that is 2.0 SD below that of healthy people (70
vs 100). However, half of the healthy population is per-
forming within 2 SD of the mean of people with schiz-
ophrenia, and 35% of the people with schizophrenia
perform within 2.0 SD of the mean of the healthy pop-
ulation. While a score of 115 would be much more rare
for someone with schizophrenia than a healthy individ-
ual, a score of 85 would be at the 67th percentile for
someone with schizophrenia and at the 17th for the
healthy population; both of these are clearly within not
outlying scores. 
An additional intriguing result of the Zakzanis et al
analyses is that many of the tests that are often described
as capturing fundamental characteristics of illnesses such
as schizophrenia fare relatively poorly when evaluated
with differential diagnostic standards. For instance, the
Wisconsin Card Sorting test,
23 a multidimensional test of
executive functioning, is associated with 40% overlap
between the performance of patients and healthy con-
trols. In schizophrenia, in fact, the top five discrimina-
tors, all associated with 20% or less overlap, are in the
domains of verbal and visuospatial memory. In the
domain of chronic multiple sclerosis only 1 test is asso-
ciated with less than 25% overlap between healthy indi-
viduals and MS patients, while many of the tests are
associated with about 50% overlap between MS patients
and healthy controls. These tests would provide essen-
tially no data useful for differential diagnosis. There are
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some areas where there a number of excellent differen-
tial diagnostic candidates. In the domain of AD there are
15 different tests, all of memory, that are associated with
less than 5% overlap between healthy controls and AD
samples. Similarly, the difference between schizophrenia
patients and AD patients on delayed recall memory was
found to be similar to differences between healthy con-
trols and AD patients.
Assessment of functional potential and the course of
degenerative conditions
One of the more robust correlations in research in men-
tal health is the association between cognitive perfor-
mance and achievements in everyday functioning. This
relationship has been appreciated for over 30 years and
has been replicated across multiple neuropsychiatric
conditions. Table II shows multiple examples of exactly
this type of relationship. There are also several addi-
tional important points about these findings. These find-
ings tend to be most robust for global aspects of cogni-
tive performance, as indexed by performance on
composite measures. In fact, in one recent study in
severe mental illness the predictive power of a compos-
ite score for correlation with functional deficits was 2 to
3 times as great as any individual neuropsychological
measure.
30 Similarly, functional deficits in AD are more
severe and debilitating after the illness has progressed,
and there are multiple cognitive processes affected.
Although it is quite possible to have functional deficits
originating from a single residual cognitive deficit, on
average more wide-ranging cognitive deficits, even if
moderate in nature, leader to broader functional deficits.
There will always be individual cases where a single,
apparently delineated, cognitive deficit leads to gross
impairment in functioning. 
The most important clinical implication of what we
know about cognition and functioning is this: when indi-
viduals affected by a neuropsychiatric condition are
found to have current cognitive abilities congruent with
pre-illness functioning they are least likely to have func-
tional deficits. This is particularly true in conditions such
Figure 1. Normative data compared with a schizophrenia sample on the RBANS neuropsychological test. RBANS, Repeatable Battery for Assessments
of Neuropsychological Status
0
<50-50
Total scale score
%
 
o
f
 
c
a
s
e
s
0
10
15
20
25
30
35
51-60 61-70 71-80 81-90 91-100 101-110 111-120 121-130 131-140 140+
7.2%
0% 0.4%
1.6%
7.0%
22.8% 22.6%
16.0%
16.5%
25.0%
7.9%
25.0%
Schizophrenia (n=575)
Normal controls (n=540)
2.2%
16.0%
0.4%
7.0%
1.6%
0.4% 0% 0% 0%
20.6%
￿ Reduced cognitive impairment post TBI predicts greater potential 
for functional recovery
25
￿ Progression of cognitive impairments leads to functional decline 
in Alzheimer’s disease
26
￿ Cognitive impairments predict everyday functional deficits in 
people with schizophrenia
27
￿ Cognitive impairments in schizophrenia and bipolar disorders 
have nearly identical relationships with everyday functioning
28
￿ Cognitive impairments in Parkinson’s disease are associated with 
functional deficits consistent with dementia
29
Table II. Neuropsychiatric conditions where cognitive functioning predicts
everyday functioning.
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31 or traumatic brain injury
(TBI)
32 where changes can occur in the context of unim-
paired previous functioning. Multiple studies of TBI
have also have shown that recovery of cognitive func-
tioning predicts recovery of everyday functioning much
more efficiently than measures of the “severity” of the
injury and some studies of TBI have had some success
in the identification of the most efficient predictors of
recovery of functioning. They tend to be from the
domains of executive functioning and processing speed,
but some studies also suggest that memory measures
may be important (see ref 33, p 12).
It has proven difficult to establish absolute standards for
how much impairment in cognitive functioning will def-
initely lead to functional changes. In addition, the search
for specific cognitive to functional relationships has also
proven challenging in conditions other than TBI. The
group average data do suggest some general guidance,
but clinical prediction will require analyses of specific
cases. What is clear, however, is that neuropsychological
assessment is an excellent tool for the prediction of
recovery.
Assessment of changes in cognition in progressive
degenerative conditions requires a different approach
than required for the initial diagnosis of dementia or
the assessment of improvement following TBI. If
delayed recall performance is at a level that is close to
0 at the time that dementia is detected, this ability will
not be a feature of the illness with the potential to
change over time. In fact, research comparing individ-
uals with AD at different levels of illness duration (and
progressive course) have suggested that there is a pat-
tern of progression in the worsening of cognitive
impairments, with delayed recall nearly completely
absent at the time of diagnosis, with other changes
occurring in close temporal proximity, including reduc-
tions in rate of learning, executive functioning, and pro-
cessing speed. Later on in the course, changes in long-
term memory such as confrontation naming are
detected and spatial and perceptual deficits become
more severe.
12-13These changes are not necessarily uni-
form or predictable for individual cases and many indi-
viduals will manifest impairments in one ability area
that are more severe than expected by their current
stage of illness. What is clear from research, however,
is that in individuals with AD and considerable cogni-
tive impairments, functional performance tends to
worsen quite markedly.
Measurement of recovery of functioning and treatment
response
There is major interest in treatment of cognitive deficits
in degenerative conditions, attention-deficit disorder,
and severe mental illness. These approaches have ranged
from in person and computerized cognitive remediation
efforts to multiple pharmacological interventions. It
makes sense that the same measures of cognitive func-
tioning used to identify functionally relevant deficits
across different neuropsychiatric conditions would be
used to measure treatment outcomes. This approach has
been used in multiple different studies, although there
are some issues that require attention in interpreting the
results of the studies. These include changes in perfor-
mance that are due to random variation and practice
effects and the fact that certain cognitive measures are
more vulnerable to these effects than others, limiting
their utility as outcome measures. One of the things that
will render neuropsychological assessment consistently
important is the new development of rehabilitation ther-
apies. Development and marketing of computerized cog-
nitive remediation interventions has not always been
accompanied by the systematic assessment of their effi-
cacy and long-term usefulness. It seems likely the per-
formance on structured neuropsychological measures
will continue to be the gold standard for selection of
patients for these interventions and evaluation of their
efficacy.
One of the strategies that has been developed to under-
stand “real” cognitive improvements vs psychometric
artifacts is the “reliable change index (RCI)” method.
34
The RCI adjusts for expected practice effects and unre-
liability of measures in order to develop an index of
change on an individual basis that would be definitely
non-random. Essentially, a statistic is calculated that
takes test scores at two different times and examines the
difference between them, establishing a range of scores
that could be attributed to practice effects or unreliabil-
ity of measures. Differences that exceed this range are
then considered to be reliable. Thus, measures with
greater test-retest reliability and smaller practice effects
in healthy controls would be better candidates for detec-
tion of small amounts of change that would still be clin-
ically meaningful. Previous results in severe mental ill-
ness have suggested that changes in typically
administered cognitive assessment batteries would need
to be in the vicinity of 1.0
35-36 standard deviations on the
96
Clinical research
PAGES_12_AG_1006_BA.qxd:DCNS#52  10/03/12  12:47  Page 96part of an individual patient to be nonrandom, suggest-
ing that quite substantial improvements may be required
with current instrumentation.
Reduction, or at least the clear recognition, of practice
effects is an important goal, because large practice
effects in treatment studies on the part of the patients in
the inactive treatment group can make it impossible to
detect change in the treatment group.
37 Certain measures
are particularly vulnerable to such effects, and some of
them may actually change in their characteristics upon
repeated administration. Episodic memory tests are par-
ticularly vulnerable to practice effects, because of the
possibility of learning of the content. However, it is crit-
ical to have alternate forms of such measures be closely
equivalent, because if the alternate forms are different
in their difficulty, an apparently improvement effect can
be spuriously detected. Problem-solving tests are quite
vulnerable to changes with retesting, because if there is
only one problem, like in the widely used Wisconsin
Card Sorting Test, once it is solved the test is no longer
a problem-solving test. As a result, systematic efforts to
develop problem-solving tests with similarly problems
(like mazes) but with alternative stimuli have been con-
ducted. 
One of the major issues in using neuropsychological
assessment as a sole outcome measure to measure either
spontaneous recovery or treatment response is the lack
of definitive information as to how much change is
required to be important. In a sense, this is the converse
of how much worsening due to illness or injury is signif-
icant, because both are equally hard to define without
additional reference points. For an adequately powered
randomized trial, separation of active treatment from
inactive treatment is certainly one standard; one that will
be applied by regulatory agencies. Another perspective
is the empirically derived standard described above a ½
standard deviation improvement as having clinical
meaning. A third strategy, which is optimal in certain cir-
cumstances where it can be applied, is that of using con-
current assessment of functional outcomes. As improve-
ment in functioning is the goal of treatment of cognition,
whenever possible improvements in functioning occur,
accompanying cognitive improvements should be mea-
sured.
For instance, in a study of cognitive remediation in schiz-
ophrenia published a few years ago, the level of
improvement in neuropsychological test performance on
the part of patients was less than 0.5 SD compared with
the inactive treatment group.
38 However, the patients
who received cognitive remediation were able to work
much more effectively and earned more than 10 times
as much money in the ensuing 3-year follow-up period
compared with patients randomized to the inactive treat-
ment.
39Thus, the cognitive improvement seen must have
been adequate for some patients, in order for them to
achieve such substantial functional gains. 
The above study is different from many other studies
because of its duration and because of the fact that
patients who entered were all receiving a psychosocial
intervention: supported employment. Such concurrent
interventions have been shown to be a prerequisite for
functional gains in cognitive remediation studies in
severe mental illness.
40 In studies where treatments are
offered for briefer periods, such as pharmacological effi-
cacy studies, or in cases where patients are not receiving
concurrent psychosocial interventions, such outcome
measures would not be practical. A suggested approach
has been to use performance-based measures of func-
tional capacity,
41 which have shown considerable valid-
ity in terms of prediction of everyday outcomes and sen-
sitivity to functional decline in very elderly patients with
severe mental illness. These measures, because they cap-
ture ability and not everyday outcomes, do not require
environmental opportunities to perform skills and have
been shown to be sensitive to the effects of short-term
behavioral interventions.
Clinical correlation
Among the exciting developments in medical technol-
ogy has been the advent of high-resolution structural
and functioning imaging of the brain. These techniques
allow for highly precise examination of lesions associ-
ated with TBI and stroke. They also can identify poten-
tially dangerous vascular abnormalities which may be
repaired before catastrophic ruptures. Also possible is
the visualization of previous “silent” ischemic changes,
strokes, and other potential lesions. With the advent of
ligands that can label amyloid,
42 it will also likely be the
case that many individuals will be informed that they
have substantial potential to experience degenerative
changes. A major question that arises after detection of
any such a brain change is whether there is any func-
tional importance of these changes. Given the consistent
findings that cortical degenerative changes are often
found at postmortem in individuals who had no obser-
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during life,
43 there will be considerable need to perform
cognitive assessments following such scans. Similarly, ser-
ial neuropsychological assessment will likely provide
better (and cheaper) information about changes in cog-
nitive functioning than repeated scans. 
Conclusions
Neuropsychological assessment has multiple clinical
applications, ranging from collecting diagnostic infor-
mation for dementia to predicting functionality and
recovery from TBI. These assessments are not likely to
be replaced by technology, because of the issues,
reviewed immediately above, regarding the lack of clear
prediction of cognition and functioning from cortical
changes in late life. Neuropsychological testing does not
provide differential diagnostic information for neu-
ropsychiatric disorders, but it provides information that
cannot be obtained anywhere else on abilities, motiva-
tion, and potential for future outcomes. There are likely
to be new advances in assessment technology, but not
assessment philosophy, over time. These improvements
may include validly deliverable remote assessments and
increased ease of administration of assessment tools. At
this time, neuropsychological assessment has many uses
and adds critical information to psychological, neuro-
logical, and neuroimaging assessments. ❏
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Aplicaciones clínicas de la evaluación 
neuropsicológica
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que la presencia de importantes cambios cerebra-
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cognitivo cercano a lo normal y que individuos sin
lesiones detectables en las imágenes pueden tener
limitaciones significativas tanto cognitivas como
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Applications cliniques de l’évaluation 
neuropsychologique
L’évaluation neuropsychologique est une méthode
basée sur la performance permettant  d’évaluer le
fonctionnement cognitif. Cette méthode est utilisée
pour analyser les conséquences cognitives des lésions
cérébrales, de la pathologie cérébrale et des mala-
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gré les avancées technologiques de l’imagerie, car il
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nement cérébral presque normal tandis que cer-
taines personnes sans lésion détectable à l’imagerie
peuvent présenter des limitations fonctionnelles et
cognitives importantes.
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